Get the Stockscreener App
5.23
4.56%
-0.25
After Hours:
5.20
-0.03
-0.57%
Aclaris Therapeutics Inc stock is traded at $5.23, with a volume of 760.53K.
It is down -4.56% in the last 24 hours and up +9.19% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
See More
Previous Close:
$5.48
Open:
$5.52
24h Volume:
760.53K
Relative Volume:
0.48
Market Cap:
$730.44M
Revenue:
$8.37M
Net Income/Loss:
$-69.66M
P/E Ratio:
-9.3326
EPS:
-0.5604
Net Cash Flow:
$-51.45M
1W Performance:
-7.92%
1M Performance:
+9.19%
6M Performance:
+16.22%
1Y Performance:
+211.31%
1-Day Range:
$5.21
$5.54
1-Week Range:
$5.21
$5.88
52-Week Range:
$1.46
$5.88
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
5.23 | 730.44M | 8.37M | -69.66M | -51.45M | -0.5604 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | Oppenheimer | Outperform |
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Aclaris Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACRS - TradingView
Piper Sandler Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS) - The Globe and Mail
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Vitiligo Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Dermira, Amgen, Pfizer, Dermavant Sciences, Incyte, TWi Biotechnology, Aclaris - Barchart.com
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Finance
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2500 Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2000 Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 3000E Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Price to book forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Enterprise value to EBIT forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView
Price to earnings forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Price to earnings forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView
Enterprise value to EBITDA forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Aclaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRS) - TradingView
ACRS Forecast — Price Target — Prediction for 2027 - TradingView
ACRS Q1 2026 Earnings: Narrows Loss Per Share as Pre-Revenue Biotech Advances PipelineProfit Cycle Analysis - dars.gov.et
We Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business Growth - Moomoo
ACRS Q1 2026 Earnings: Slimmer Loss Beats Estimates as Stock ReboundsReturn On Capital - DonanımHaber
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
3 penny stocks under $5 backed by real revenue growth - MSN
Aclaris Therapeutics Inc (ACRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aclaris Therapeutics Inc (ACRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aclaris Therapeutics Inc (ACRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aclaris Therapeutics Inc (ACRS) Institutional Confidence - TradingKey
Aclaris Therapeutics Inc (ACRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aclaris Therapeutics Inc (ACRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aclaris Therapeutics Inc (ACRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aclaris Therapeutics Inc (ACRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aclaris Therapeutics Inc (ACRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aclaris Therapeutics Holds Steady Near Support as Biotech Sector Watches Key LevelsMomentum Factor - newsline.com
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
Aclaris Therapeutics (ACRS) Gains Analyst Attention as Stifel Flags Penny Stock OpportunityEarnings Revision Report - newsline.com
Aclaris (ACRS) director Andrew Schiff reports RSU vesting and new stock option grant - Stock Titan
Aclaris Therapeutics (ACRS) director gains new RSUs and stock options - Stock Titan
Stifel Raises Aclaris Therapeutics Price Target to Four Dollars - HarianBasis.co
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On - Insider Monkey
Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052 - MSN
Aclaris Stockholders Approve Directors, Pay and Auditor - The Globe and Mail
Shareholders at Aclaris (NASDAQ: ACRS) back directors, executive pay and PwC - Stock Titan
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 - Yahoo Finance
ACRS: All proposals passed, with no stockholder questions submitted during the meeting - TradingView
Q2 Earnings Forecast for ACRS Issued By Lifesci Capital - MarketBeat
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday - Benzinga
Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital - Moomoo
ACRS Initiated Coverage by LifeSci Capital -- Rating 'Outperform' - GuruFocus
Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data - Bez Kabli
ACRSAclaris Therapeutics Inc Latest SEC Filings - Finviz
ACRS Q1 2026 Earnings: Smaller-than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Acceleration Picks - newsline.com
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):